Overall, 13 cancer hallmarks were significantly upregulated in the MCL cells from patient B (the non-responder), including MYC, OXPHOS, BCR, mTORC1, cell cycle, and PI3K/AKT/mTOR signaling (Fig. 2b, c and Supplementary Fig. 5b, c). This evidence concerns the gene BCR and mantle cell lymphoma.